Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of Rugonersen in Healthy Men
NCT04863794Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rugonersen in Angelman syndrome (AS), sponsored by Roche. Primary endpoint: Quantification of [89Zr]DFO-RO7248824 distribution within the central nervous system (CNS). Started Apr 2021; status: completed.
02
Drugs
rugonersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT04863794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863794.